Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism

European Heart Journal

Volumn 35, Issue 28, 2014, Pages 1836-1843

  Fontana, Pierre ^a   Goldhaber, Samuel Z ^b   Bounameaux, Henri ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Anticoagulant; Deep venous thrombosis; Direct factor Xa inhibitors; Direct thrombin inhibitors; Pulmonary embolism

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; ANTITHROMBIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; THIAZOLE DERIVATIVE; THIOPHENE DERIVATIVE; VITAMIN K GROUP;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; HUMAN; LABORATORY TEST; LONG TERM CARE; OUTPATIENT CARE; PERIOPERATIVE PERIOD; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); VENOUS THROMBOEMBOLISM; ACUTE DISEASE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; HEMORRHAGE; ORAL DRUG ADMINISTRATION; PROCEDURES; PULMONARY EMBOLISM; TREATMENT OUTCOME;

ACUTE DISEASE; ADMINISTRATION, ORAL; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; CLINICAL TRIALS, PHASE III AS TOPIC; HEMORRHAGE; HUMANS; LONG-TERM CARE; MORPHOLINES; PERIOPERATIVE CARE; PULMONARY EMBOLISM; PYRAZOLES; PYRIDINES; PYRIDONES; THIAZOLES; THIOPHENES; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VITAMIN K;

EID: 84905020676     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu027     Document Type: Article

References (37)

1. Mavrakanas T, Bounameaux H. The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism. Pharmacol Ther 2011;130:46-58
2. Franchini M, Mannucci PM. New anticoagulants for treatment of venous thromboembolism. Eur J Intern Med 2012;23:692-695
3. Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: Population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011;50:675-686
4. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008;47:285-295
5. Scaglione F. New oral anticoagulants: Comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet 2013;52:69-82
6. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995;13:129-134
7. Schulman S, Crowther MA. How I treat with anticoagulants in 2012: New and old anticoagulants, and when and how to switch. Blood 2012;119:3016-3023
8. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR. Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e419S-e494S.
9. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet 2012;379:1835-1846
10. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-2352
11. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363: 2499-2510
12. Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366:1287-1297
13. Prins MH, Lensin AW, Bauersachs R, Van Bellen B, Bounameaux H, Brighton T, Cohen AT, Davidson BL, Decousus H, Raskob GE, Wells P. Oral rivaroxaban for the treatment of symptomatic venous thromboembolism: A pooled analysis. Thromb J 2013;11:21
14. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369:799-808
15. Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. The Hokusai-VTE Investigators. N Engl J Med 2013;369:1406-1415
16. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013;368:709-718
17. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013;368:699-708
18. Fox BD, Kahn SR, Langleben D, Eisenberg MJ, Shimony A. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: Direct and adjusted indirect meta-Analysis of randomised controlled trials. BMJ 2012;345: E7498
19. Lefebvre P, Coleman CI, Bookhart BK, Wang ST, Mody SH, Tran KN, Zhuo DY, Huynh L, Nutescu EA. Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism. J Med Econ 2014;17:52-64.
20. Lecumberri R, Alfonso A, Jimenez D, Fernandez Capitan C, Prandoni P, Wells PS, Vidal G, Barillari G, Monreal M. Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism. Thromb Haemost 2013;110:834-843
21. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial. Lancet 2010;376:975-983
22. Garcia D, Barrett YC, Ramacciotti E, Weitz JI. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost 2013;11:245-252
23. Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med 2011;49:761-772
24. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012;23: 138-143
25. Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, AgenoW. Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2013;11:756-760
26. Hawes EM, Deal AM, Funk-Adcock D, Gosselin R, Jeanneret C, Cook AM, Taylor JM, Whinna HC, Winkler AM, Moll S. Performance of coagulation tests in patients on therapeutic doses of dabigatran: A cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost 2013;11:1493-1502
27. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH. Evidence-based management of anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e152S-e184S.
28. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P. EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. Eur Heart J 2013;34:2096-2104
29. Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, Blais N, Fontana P, Cohen A, Llau JV, Rosencher N, Schved JF, de Maistre E, Samama MM, Mismetti P, Sie P. Management of major bleeding complications and emergency surgery in patients on long-Term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of theWorking Group on Perioperative Haemostasis (GIHP)-March 2013. Arch Cardiovasc Dis 2013;32:691-700
30. Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, Chan AK, James A, Moll S, Ortel TL, VanCott EM, Ansell J. Guidance onthe emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012;87: S141-S145
31. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Sinha U. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013;19:446-451
32. Schiele F, Van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, Nar H, Litzenburger T. A specific antidote for dabigatran: Functional and structural characterization. Blood 2013;121:3554-3562
33. Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn AS, Kunz R. Perioperative management of antithrombotic therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e326S-e350S.
34. Sie P, Samama CM, Godier A, Rosencher N, Steib A, Llau JV, Van Der Linden P, Pernod G, Lecompte T, Gouin-Thibault I, Albaladejo P. Surgery and invasive procedures in patients on long-Term treatment with direct oral anticoagulants: Thrombin or factor-Xa inhibitors. Recommendations of theWorking Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. Arch Cardiovasc Dis 2011;104:669-676
35. Llau JV, Ferrandis R. Letter by Llau and Ferrandis regarding article, 'Bridging evidencebased practice and practice-based evidence in periprocedural anticoagulation-. Circulation 2013;127:e616
36. Ferrandis R, Castillo J, de Andres J, Gomar C, Gomez-Luque A, Hidalgo F, Llau JV, Sierra P, Torres LM. The perioperative management of new direct oral anticoagulants: A question without answers. Thromb Haemost 2013;110:515-522
37. Bonhomme F, Hafezi F, Boehlen F, HabreW. Management of antithrombotic therapies in patients scheduled for eye surgery. Eur J Anaesthesiol 2013;30:449-454.